Jeannette Potts Sells 5,237 Shares of uniQure (NASDAQ:QURE) Stock

uniQure N.V. (NASDAQ:QURE) insider Jeannette Potts sold 5,237 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $27.67, for a total value of $144,907.79. Following the completion of the sale, the insider directly owned 133,246 shares of the company’s stock, valued at approximately $3,686,916.82. The trade was a 3.78% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

uniQure Stock Up 78.4%

Shares of NASDAQ QURE traded up $21.17 during trading hours on Wednesday, hitting $48.16. The stock had a trading volume of 19,686,317 shares, compared to its average volume of 2,718,284. The company has a market capitalization of $3.04 billion, a P/E ratio of -13.84 and a beta of 0.98. The firm’s 50-day moving average price is $22.93 and its two-hundred day moving average price is $21.75. uniQure N.V. has a 52 week low of $8.73 and a 52 week high of $71.50. The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.40 and a current ratio of 10.40.

uniQure (NASDAQ:QURE) last announced its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.03. The business had revenue of $3.56 million during the quarter, compared to analysts’ expectations of $5.21 million. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%. Analysts anticipate that uniQure N.V. will post -3.64 EPS for the current fiscal year.

Institutional Investors Weigh In On uniQure

A number of large investors have recently added to or reduced their stakes in QURE. State Street Corp boosted its position in uniQure by 123.8% during the fourth quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock worth $77,319,000 after purchasing an additional 1,787,033 shares during the period. JPMorgan Chase & Co. boosted its position in uniQure by 155.3% during the fourth quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock worth $70,226,000 after purchasing an additional 1,785,275 shares during the period. Avoro Capital Advisors LLC boosted its position in uniQure by 38.4% during the fourth quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock worth $147,170,000 after purchasing an additional 1,705,556 shares during the period. Orbimed Advisors LLC boosted its position in uniQure by 189.7% during the first quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company’s stock worth $34,926,000 after purchasing an additional 1,398,749 shares during the period. Finally, MPM Bioimpact LLC bought a new stake in uniQure during the fourth quarter worth approximately $33,062,000. Institutional investors own 78.83% of the company’s stock.

Wall Street Analyst Weigh In

QURE has been the subject of several recent research reports. Wall Street Zen raised uniQure from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. Royal Bank Of Canada raised uniQure from a “sector perform” rating to an “outperform” rating and boosted their price target for the company from $11.00 to $35.00 in a research note on Monday, March 9th. HC Wainwright lowered their price target on uniQure from $70.00 to $50.00 and set a “buy” rating for the company in a research note on Wednesday, May 6th. Wells Fargo & Company raised uniQure from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $15.00 to $60.00 in a research note on Monday, March 9th. Finally, Mizuho raised uniQure from a “neutral” rating to an “outperform” rating and upped their target price for the stock from $12.00 to $35.00 in a research report on Wednesday, March 11th. Twelve analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, uniQure has a consensus rating of “Moderate Buy” and a consensus price target of $47.17.

More uniQure News

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: The FDA agreed that uniQure’s three-year Phase I/II data for AMT-130 could support a Biologics License Application, reopening a near-term path to accelerated approval and materially improving the drug’s chances of reaching the market. Article Title
• Positive Sentiment: uniQure said it plans to file for FDA approval in the third quarter, signaling that a regulatory submission is now back on track after earlier concerns that the company would need a larger Phase III trial. Article Title
• Positive Sentiment: Analyst sentiment improved, with Cantor Fitzgerald upgrading QURE to overweight and setting a $61 price target, adding to the bullish momentum. Article Title
• Neutral Sentiment: Options activity jumped as traders positioned for the move, with unusually heavy call buying suggesting heightened speculation around the FDA news.
• Negative Sentiment: The stock’s rapid surge may also reflect short-covering and extreme volatility, which can increase the risk of sharp pullbacks if investors reassess how durable the FDA optimism really is.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.